Gilead extends an oncology discovery program with Nurix for two years
Company / institutional announcement · Nurix Therapeutics
Source published:
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Nurix and Gilead agreed to extend research on an undisclosed oncology program by another two years, marking the program’s second extension. Their collaboration uses E3 ligases to induce degradation of selected targets. Nurix retains options, subject to restrictions, to share development, commercialization, and profits and losses equally in the United States for up to two programs.
Why it may matter
Continued partner investment supports the discovery platform, although undisclosed targets and candidate details limit assessment of the program’s specific development prospects.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections